AVEO Pharmaceuticals Inc. (AVEO)

0.96
0.03 2.90
NASDAQ : Health Technology
Prev Close 0.99
Open 1.00
Day Low/High 0.95 / 1.01
52 Wk Low/High 0.49 / 3.59
Volume 864.81K
Avg Volume 3.01M
Exchange NASDAQ
Shares Outstanding 160.74M
Market Cap 168.78M
P/E Ratio N/A
Div & Yield N.A. (N.A)
AVEO Oncology To Present At The 31st Annual J.P. Morgan Healthcare Conference

AVEO Oncology To Present At The 31st Annual J.P. Morgan Healthcare Conference

AVEO Oncology (NASDAQ: AVEO) today announced that Tuan Ha-Ngoc, president and chief executive officer, is scheduled to present at the 31 st Annual J.

Put These Flyers Under Your Tree

These stocks may be speculative, but they sport solid sales-growth estimates -- and insiders are buying.  

AVEO Oncology Appoints Robert Epstein, M.D., M.S. To Its Board Of Directors

AVEO Oncology Appoints Robert Epstein, M.D., M.S. To Its Board Of Directors

AVEO Oncology (NASDAQ: AVEO) today announced the appointment of Robert Epstein, M.

Insider Buying at Auxilium, Aveo Hints At Big Moves in 2013

Insider Buying at Auxilium, Aveo Hints At Big Moves in 2013

Insiders at Auxilium and Aveo appear to be betting on turnarounds for both stocks in the next year.

5 Stock Insiders are Gobbling Up

5 Stock Insiders are Gobbling Up

But insiders usually buy their own shares for one reason: They think the stock is a bargain and has tremendous upside.

2013 FDA Drug Approval Decision Calendar

2013 FDA Drug Approval Decision Calendar

A list of stocks with drugs expecting FDA decisions in 2013

Walking Away From the Cliff

Some traders are shutting down for the year rather than trying to game the fiscal cliff.

AVEO And Astellas Announce Initiation Of Patient Enrollment In Phase 2 Trial Of Tivozanib In Combination With Paclitaxel In Patients With Advanced Triple Negative Breast Cancer

AVEO And Astellas Announce Initiation Of Patient Enrollment In Phase 2 Trial Of Tivozanib In Combination With Paclitaxel In Patients With Advanced Triple Negative Breast Cancer

AVEO Oncology (NASDAQ: AVEO) and Astellas Pharma Inc. (TSE: 4503) today announced the initiation of patient enrollment in a randomized, double-blind, multicenter Phase 2 clinical trial, called BATON-BC, evaluating...

AVEO And Astellas Announce FDA Acceptance Of NDA Filing For Tivozanib For The Treatment Of Advanced Renal Cell Carcinoma

AVEO And Astellas Announce FDA Acceptance Of NDA Filing For Tivozanib For The Treatment Of Advanced Renal Cell Carcinoma

AVEO Oncology (NASDAQ: AVEO) and Astellas Pharma Inc. (TSE: 4503) today announced that the U.

AVEO Oncology To Present At The Deutsche Bank 2012 DbAccess BioFEST Conference

AVEO Oncology To Present At The Deutsche Bank 2012 DbAccess BioFEST Conference

AVEO Oncology (NASDAQ: AVEO) today announced that David Johnston, chief financial officer, is scheduled to present at the Deutsche Bank 2012 dbAccess BioFEST Conference on Monday, December 3, 2012 at 4:35 p.

Biotech Stock Mailbag: Aveo, Anthera, Amarin, MAP Pharma

Biotech Stock Mailbag: Aveo, Anthera, Amarin, MAP Pharma

Biotech columnist Adam Feuerstein answers readers' questions about health-care companies

AVEO Oncology To Present At The Lazard Capital Markets 9th Annual Healthcare Conference

AVEO Oncology To Present At The Lazard Capital Markets 9th Annual Healthcare Conference

AVEO Oncology (NASDAQ: AVEO) today announced that David Johnston, chief financial officer, is scheduled to present at the Lazard Capital Markets 9th Annual Healthcare Conference on Tuesday, November 13, 2012 at 1:00 p.

AVEO Announces Strategic Restructuring And Provides Third Quarter Financial Results

AVEO Announces Strategic Restructuring And Provides Third Quarter Financial Results

AVEO Oncology (NASDAQ: AVEO) today announced a strategic restructuring designed to optimize resources and reduce expenses to ensure AVEO is well positioned for a successful launch of tivozanib in renal cell carcinoma...

AVEO Oncology Announces Timing For Third Quarter Financial Results, Webcast And Conference Call

AVEO Oncology Announces Timing For Third Quarter Financial Results, Webcast And Conference Call

AVEO Oncology (NASDAQ: AVEO) today announced that financial results for the company’s third quarter ended September 30, 2012 will be released before the market opens on Tuesday, October 30, 2012.

AVEO And Astellas Announce New Data Presented At ESMO 2012 Congress Demonstrating The Safety And Tolerability Profile Of Tivozanib In Patients With Advanced Kidney Cancer

AVEO And Astellas Announce New Data Presented At ESMO 2012 Congress Demonstrating The Safety And Tolerability Profile Of Tivozanib In Patients With Advanced Kidney Cancer

AVEO Oncology (NASDAQ: AVEO) and Astellas Pharma Inc. (TSE: 4503) today announced new data from the Phase 3 TIVO-1 trial ( TIvozanib Versus s Orafenib in 1 st line advanced RCC) demonstrating the safety and...

AVEO Announces Detailed Results Of Exploratory Phase 2 Study Evaluating Ficlatuzumab In First-Line Patients With Advanced Non-small Cell Lung Cancer; New Data Presented At ESMO

AVEO Announces Detailed Results Of Exploratory Phase 2 Study Evaluating Ficlatuzumab In First-Line Patients With Advanced Non-small Cell Lung Cancer; New Data Presented At ESMO

AVEO Oncology (NASDAQ: AVEO) today announced that detailed results from an exploratory, randomized Phase 2 study evaluating the combination of ficlatuzumab, the company’s HGF inhibitory antibody, and gefitinib ...

AVEO And Astellas Announce Submission Of New Drug Application For Tivozanib For The Treatment Of Advanced Renal Cell Carcinoma

AVEO And Astellas Announce Submission Of New Drug Application For Tivozanib For The Treatment Of Advanced Renal Cell Carcinoma

AVEO Oncology (NASDAQ: AVEO) and Astellas Pharma Inc. (TSE:4503) today announced that AVEO has submitted a New Drug Application (NDA) to the U.

New Clinical Data On AVEO Oncology’s Tivozanib And Ficlatuzumab To Be Presented At The ESMO 2012 Congress

New Clinical Data On AVEO Oncology’s Tivozanib And Ficlatuzumab To Be Presented At The ESMO 2012 Congress

AVEO Oncology (NASDAQ: AVEO) today announced that new clinical data on its lead product candidate tivozanib, partnered with Astellas Pharma Inc.

AVEO Oncology To Present At The UBS Annual Global Life Sciences Conference

AVEO Oncology To Present At The UBS Annual Global Life Sciences Conference

AVEO Oncology (NASDAQ: AVEO) today announced that David Johnston, chief financial officer, is scheduled to present at the UBS Annual Global Life Sciences Conference on Thursday, September 20, 2012 at 2:00 p.

AVEO Oncology To Present At The Morgan Stanley Global Healthcare Conference

AVEO Oncology To Present At The Morgan Stanley Global Healthcare Conference

AVEO Oncology (NASDAQ: AVEO) today announced that David Johnston, chief financial officer, is scheduled to present at the Morgan Stanley Global Healthcare Conference on Monday, September 10, 2012 at 10:35 a.

AVEO Oncology To Present At The Canaccord Genuity 32nd Annual Growth Conference

AVEO Oncology To Present At The Canaccord Genuity 32nd Annual Growth Conference

AVEO Oncology (NASDAQ: AVEO) today announced that David Johnston, chief financial officer, is scheduled to present at the Canaccord Genuity 32 nd Annual Growth Conference on Thursday, August 16, 2012 at 10:00 a.

AVEO Pharmaceuticals Management Discusses Q2 2012 Results - Earnings Call Transcript

AVEO Pharmaceuticals Management Discusses Q2 2012 Results - Earnings Call Transcript

AVEO Pharmaceuticals Management Discusses Q2 2012 Results - Earnings Call Transcript

AVEO Reports Second Quarter 2012 Financial Results

AVEO Reports Second Quarter 2012 Financial Results

AVEO Oncology (NASDAQ: AVEO) today reported consolidated financial results for the second quarter of 2012, and highlighted recent developments and key second quarter accomplishments.

AVEO Oncology Announces Timing For Second Quarter Financial Results, Webcast And Conference Call

AVEO Oncology Announces Timing For Second Quarter Financial Results, Webcast And Conference Call

AVEO Oncology (NASDAQ: AVEO) today announced that financial results for the company's second quarter ended June 30, 2012 will be released before the market opens on Thursday, August 2, 2012.

AVEO And Astellas Announce TAURUS Patient Preference Clinical Study Comparing Tivozanib With Sunitinib In First-Line Kidney Cancer

AVEO And Astellas Announce TAURUS Patient Preference Clinical Study Comparing Tivozanib With Sunitinib In First-Line Kidney Cancer

AVEO Oncology (NASDAQ: AVEO) and Astellas Pharma Inc. (TSE: 4503) today announced plans to initiate a new clinical study, TAURUS ( Tivoz Anib Use ve Rs Us Sutent in advanced renal cell carcinoma (RCC): Patient...

ASCO '12 Stocks: Winners and Losers

ASCO '12 Stocks: Winners and Losers

Snap judgments in biotech and drug stocks after a weekend spent at the ASCO cancer meeting.

ASCO 2012 Live Blog -- Saturday

ASCO 2012 Live Blog -- Saturday

TheStreet's biotech columnist Adam Feuerstein brings you live coverage of ASCO, the Super Bowl of cancer drug medical conferences.

AVEO Oncology To Host Conference Call And Webcast To Review Phase 3 TIVO-1 Data Presented At ASCO

AVEO Oncology To Host Conference Call And Webcast To Review Phase 3 TIVO-1 Data Presented At ASCO

AVEO Oncology (Nasdaq: AVEO) today announced that the AVEO management team will host a conference call on Monday, June 4, 2012 at 7:30 a.

AVEO Oncology To Present At The Jefferies 2012 Global Healthcare Conference

AVEO Oncology To Present At The Jefferies 2012 Global Healthcare Conference

AVEO Oncology (Nasdaq: AVEO) today announced that David Johnston, chief financial officer, is scheduled to present at the Jefferies 2012 Global Healthcare Conference on Tuesday, June 5, 2012 at 3:00 p.

AVEO Initiates Phase 1 Study Of AV-203, An ERBB3 Inhibitory Antibody, In Advanced Solid Tumors

AVEO Initiates Phase 1 Study Of AV-203, An ERBB3 Inhibitory Antibody, In Advanced Solid Tumors

AVEO Oncology (Nasdaq: AVEO) today announced the initiation of a Phase 1 study examining the safety and preliminary efficacy of AV-203 along with exploratory biomarkers in patients with advanced solid tumors.

TheStreet Quant Rating: D- (Sell)